PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “YTTRIUM”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1996

Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography.

Yttrium-90 is used for palliative therapy for the treatment of skeletal metastases, but because it is a pure beta- emitter, data on the pharmacokinetics and radiation doses to metastases and unaffected organs are lacking. To obtain such data, the present study employed yttrium-86 as a substitute for 90Y, with detection by positron emission tomography (PET). The study compared the properties of two different 86Y complexes - 86Y-citrate and 86Y-ethylene diamine tetramethylene phosphonate (EDTMP) - in ten patients with prostatic cancer who had developed multiple bone metastases (the ten patients being divided into two groups of five). Early dynamics were measured up to 1 h post injection (p.i.) over the liver region, followed by subsequent whole-body PET scans up to 3 days p.i. Absolute uptake data were determined for normal bone, bone metastases, liver and kidney. Radiation doses were calculated according to the MIRD recommendations. Based on the pharmacokinetic measurements of the distribution of the 86Y complexes, it was possible to calculate radiation doses for the bone metastases and the red bone marrow delivered by complexes containing 90Y. In 1 cm3 of bone metastasis, doses of 26+/-11 mGy/MBq and 18+/-2 mGy/MBq were determined per MBq of injected 90Y-citrate and 90Y-EDTMP, respectively. The doses to the bone marrow were 2.5+/-0.4 mGy/MBq for 90Y-citrate and 1.8+/-0.6 mGy/MBq for 90Y-EDTMP. 86Y and PET provide quantitative information applicable to the clinical use of 90Y. This method may also be useful for the design of other 90Y radiopharmaceuticals and for planning radiotherapy dosages.

Aged↗
PubMed2006

Urinary yttrium excretion and effects of yttrium chloride on renal function in rats.

Evaluation of yttrium exposure in biological samples has not been fully examined. To evaluate yttrium nephrotoxicity, yttrium chloride was orally administered to male Wistar rats and the urine volume (UV) and N-acetyl-beta-D-glucosaminidase (NAG) and creatinine excretion (Crt) were measured in 24-h urine samples. The urinary yttrium concentration and excretion rate were determined by inductively coupled plasma-argon emission spectrometry (ICP-AES). Large significant decreases of UV (>30%) and Crt (>10%) were observed at yttrium doses of 58.3-116.7 mg per rat, but no significant NAG changes was observed. This response pattern shows that a high yttrium dosage alters glomerular function rather than the proximal convoluted tubules. A urinary yttrium excretion rate of 0.216% and good dose-dependent urinary excretion (r=0.77) were confirmed. These results suggest that urinary yttrium is a suitable indicator of occupational and environmental exposure to this element, an increasingly important health issue because recent technological advances present significant potential risks of exposure to rare earth elements. We propose that the ICP-AES analytical method and animal experimental model described in this study will be a valuable tool for future research on the toxicology of rare earth elements.

Acetylglucosaminidase↗
PubMed1998

Yttrium-90 biodistribution by yttrium-87 imaging: a theoretical feasibility analysis.

Yttrium-90 is widely used in radioimmunotherapy but does not emit photons for imaging. Indium-111, a chemically similar atom has been used instead as a tracer for the distribution of 90Y-labeled antibodies. Recent advances in gamma camera technology have made it possible to image at energies higher than 364 keV. This work provides a theoretical analysis of the feasibility of using 87Y (485 keV, 92.2% yield) as a tracer for in vivo imaging of 90Y-labeled antibodies. Yttrium-87 may be produced by the 87Sr(p,n)87Y reaction in a cyclotron and has a 3.3 day half-life. This reaction also yields a metastable state of 87Y (87mY). Yttrium-87, itself decays to a metastable state of 87Sr (87mSr). The level of these contaminants and their anticipated impact on the utility of 87Y as a tracer for 90Y are examined theoretically. Dosimetry is performed to assess the absorbed dose associated with using 87Y. A 100 h delay following the end of bombardment of an isotopically enriched 87Sr target reduces the activity of the metastable state of 87Y in the product by 10- to 15-fold, with greater delays resulting in a further reduction. A rapid equilibration between 87Y and its daughter, 87mSr, is expected, in vivo. Although strontium is known to concentrate in bone, the electron emissions of 87mSr are short range, thereby making possible biologic effects highly position dependent; the photon emissions allow for independent imaging which may be used to perform dosimetry and thereby directly assess potential toxicity. 87Y merits further consideration as an imaging tracer for 90Y.

Animals↗
PubMed2004

Hydrogenation of carbon dioxide and aryl isocyanates by a tetranuclear tetrahydrido yttrium complex. Isolation, structures, and CO2 insertion reactions of methylene diolate and mu3-oxo yttrium complexes.

The reaction of carbon dioxide with a tetranuclear tetrahydrido yttrium complex [(C5Me4SiMe3)Y(mu-H)]4(L) (L = Me3SiCC(H)C(H)CSiMe3) (1) rapidly afforded the corresponding bis(methylene diolate) complex [(C5Me4SiMe3)Y]4(mu-O2CH2)2(L) (2), while the reactions of an aryl isocyanate with 1 led to selective formation of the mu3-oxo complex [(C5Me4SiMe3)Y]4(mu-O)( mu-H)2(L) (5) or [(C5Me4SiMe3)Y]4(mu-O)2(L) (7), depending on the substrate ratio. Both the methylene diolate and the oxo complexes can undergo CO2 insertion reactions to give the corresponding carbonate complexes. These reactions not only yield a new series of polynuclear yttrium complexes having novel structures but also shed new light on the mechanistic aspects of the heterogeneous hydrogenation of COmicron2. The high reactivity of the polynuclear mu3-oxo yttrium complexes 5 and 7 could also make them novel molecular models for study of metal oxide-supported catalysts.

Journal Article↗
PubMed2005

Comparison of erbium:yttrium-aluminum-garnet and holmium:yttrium-aluminum-garnet lasers for incision of urethra and bladder neck in an in vivo porcine model.

OBJECTIVES: To evaluate, in an animal model, differences in wound healing and scar formation in healthy urethra and bladder neck incised with the erbium (Er):yttrium-aluminum-garnet (YAG) and holmium (Ho):YAG lasers. METHODS: In each of 18 domestic pigs, three 1-cm-long incisions were made, two at the bladder neck and one in the mid-urethra, using either the Er:YAG laser (9 pigs) or the Ho:YAG laser (9 pigs). In each laser group, 3 animals were killed on postoperative days 0, 6, and 14. The width of collateral damage, as evidenced by coagulation necrosis and granulation tissue at the wound base, and the incision depth were evaluated during tissue analysis. RESULTS: The collateral damage with the Er:YAG laser at postoperative day 0, 6, and 14 was 20 +/- 5, 900 +/- 100, and 430 +/- 100 microm, respectively. The collateral damage with the Ho:YAG laser was 660 +/- 110, 2280 +/- 700, and 1580 +/- 250 microm, respectively. The amount of granulation tissue was significantly less (P <0.05) at all time points with the Er:YAG laser. Similarly, the incision depths for the Er:YAG and Ho:YAG laser at postoperative day 6 (1100 +/- 200 microm versus 1500 +/- 300 microm, respectively) and 14 (670 +/- 140 microm versus 1240 +/- 140 microm, respectively) were also significantly less (P <0.05) for the Er:YAG laser group, indicating faster healing of the wound created. CONCLUSIONS: In this in vivo animal study, incisions in the urethra and bladder neck made with the Er:YAG laser healed faster and with less scar formation than incisions made with the Ho:YAG laser.

Aluminum↗
PubMed2006

Solvation of yttrium with ammonia revisited. Di-amide formation in the reaction of yttrium with ammonia.

The reactivity of yttrium atoms toward ammonia is revisited using expanded density functional theory calculations. The new results reveal that absorption of NH3 on YNH is dissociative to form Y(NH2)2. The di-amide species can adsorb further NH3 molecules molecularly to form Y(NH2)2NH3 and Y(NH2)2(NH3)2. The calculations aimed to reveal the detail of the potential energy curves between the imide and the di-amide forms. The Y(NH2)2(NH3)x species are more stable than those of YNH(NH3)x by more than 20 kcal/mol.

Journal Article↗
PubMed1993

Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics.

This study was performed to demonstrate the quantitative in vivo assessment of human pharmacokinetics of 90Y-radiotherapeutics using the positron-emitting substitute 86Y and PET. This technique is illustrated in a patient with disseminated bone metastases from breast cancer who was injected with 100 MBq of 86Y-citrate as an analog of the commercially available radiotherapeutic 90Y-citrate. Whole-body distribution was measured with a PET camera 4, 10, 21, 28 and 45 hr postinjection. Uptake data were determined from reconstructed transverse PET images by regions of interest placed in normal bone tissue, liver and metastases. Images of coronal and sagittal whole-body sections were obtained by reformatting the transverse PET images. The ratio of activity concentration in metastases to that in normal bone ranged from 1.5:1 to 3.5:1. Of the injected tracer, 13.4% was found in the skeleton and 0.43% in the metastasis with the highest 86Y concentration. Radiation doses per 1 MBq of injected 90Y-citrate were calculated from 86Y-citrate data and data from MIRD pamphlets 5 and 11. The doses were 1.01 MGy/MBq for red marrow, 593 microGy/MBq for the liver and approximately 3.5 MGy/MBq for the most conspicuous metastases. This study demonstrates that the use of PET via 86Y allows an individual in vivo quantification of activity uptake and radiation dose of both normal tissue and tumor in pain treatment with 90Y-labeled radiotherapeutics.

Adult↗
PubMed1989

Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity.

One factor that is critical to the potential effectiveness of radioimmunotherapy is the design of radiometal-chelated antibodies that will be stable in vivo. Stability in vivo depends on the condition that both the chelate linkage and radiolabeling procedures not alter antibody specificity and biodistribution. In addition, synthesis and selection of the chelating agent is critical for each radiometal in order to prevent inappropriate release of the radiometal in vivo. In the present study, we compare the in vivo stability of seven radioimmunoconjugates that use different polyaminocarboxylate chelating agents to complex yttrium-88 to the mouse anti-human interleukin-2 receptor monoclonal antibody, anti-Tac. Chelate linkage and radiolabeling procedures did not alter the immunospecificity of anti-Tac. In order to assess whether yttrium was inappropriately released from the chelate-coupled antibody in vivo, iodine-131-labeled and yttrium-88 chelate-coupled antibodies were simultaneously administered to the same animals to correlate the decline in yttrium and radioiodinated antibody activity. The four stable yttrium-88 chelate-coupled antibodies studied displayed similar iodine-131 and yttrium-88 activity, indicating minimal elution of yttrium-88 from the complex. In contrast, the unstable yttrium-88 chelate-coupled antibodies had serum yttrium-88 activities that declined much more rapidly than their iodine-131 activities, suggesting loss of the radiolabel yttrium-88 from the chelate. Furthermore, high rates of yttrium-88 elution correlated with deposition in bone. Four chelating agents emerged as promising immunotherapeutic reagents: isothiocyanate benzyl DTPA and its derivatives 1B3M, MX, and 1M3B. All four isothiocyanate agents showed prolonged yttrium-88 vascular survival which was essentially identical to that of their iodine-131 activity with only minimum accumulation (1.4-1.8%/g) of the yttrium-88 injected dose into bone. Thus, these four chelating agents were very stable in vivo and suitable for yttrium-monoclonal antibody radioimmunotherapy.

Animals↗
PubMed2003

Does yttrium radiosynovectomy increase the risk of cancer in patients with rheumatoid arthritis?

OBJECTIVE: To study the long term risk of cancer in patients with rheumatoid arthritis (RA) who have been treated with yttrium. METHODS: The medical record numbers of 1228 patients with RA who were admitted to hospital in 1979-85 were identified in the database of Jyväskylä Central Hospital. Radiosynovectomy of the knee joint was performed in a total of 143 patients using yttrium-90 silicate during the years 1970-85, while 1075 did not receive yttrium radiosynovectomy; 10 received yttrium treatment later than 1985 and were excluded from the analysis. The Finnish Cancer Registry database was used to examine whether the subjects had cancer during the follow up from 1979 until the end of 1999. RESULTS: Nine cases of cancer were found among the patients who had received yttrium, whereas the expected number based on the incidence among the population in the region was 14.9. The standardised incidence ratio of cancer was 0.6 (95% confidence interval (CI) 0.3 to 1.1) for the patients who received yttrium, and 1.1 (95% CI 0.9 to 1.3) for the patients who did not receive yttrium. CONCLUSIONS: Yttrium treatment did not increase the risk of cancer.

Adult↗
PubMed1997

Surface Chemical Analysis and Electrokinetic Properties of Spherical Hematite Particles Coated with Yttrium Compounds

We describe in this work the chemical and electrokinetic surface characterization of core-shell particles consisting of a practically spherical hematite nucleus coated by a layer of yttrium basic carbonate or yttrium oxide (obtained after calcination of the carbonate-coated particles, following the method of E. Matijevic and B. Aiken (J. Colloid Interface Sci. 126, 645 (1988))). The morphological and surface characteristics of the particles were controlled by modifying the initial yttrium nitrate concentration and the growing time. A total of 14 samples of hematite-yttrium basic carbonate composites were obtained, and three of them (obtained by keeping at 90degreesC solutions containing 6.5 x 10(-4) M alpha-Fe2O3, 1.8 M urea, and 1.1, 3, and 4.9 mM Y(NO3)3, respectively) were then converted into hematite-Y2O3 particles. Transmission electron microscopy was used to ascertain the shape and size of the particles. The spherical geometry of the core hematite is found, as a rule, on the core-shell particles; in general, carbonate samples obtained with intermediate initial concentration of Y(NO3)3 have the maximum coating thickness, whereas increasing that concentration does not lead to thicker coatings. Hence, formation of individual yttrium basic carbonate, together with coated hematite, cannot be completely ruled out under such conditions. Two techniques were employed for the elucidation of the surface composition of the particles, namely EDX and XPS (or ESCA). In particular, XPS data show that the coating of hematite by yttrium carbonate is almost complete in the case of particles obtained with 3 mM Y(NO3)3 concentration and 9-h heating time. The oxide samples obtained after calcination show high contents of yttrium and low iron surface concentration for initial [Y(NO3)3] = 1.1 mM (sample OB9) and 3 mM. According to XPS analysis, both types of particles have a quite similar surface composition and structure. For all types of particles but the carbonate-coated ones obtained at the shortest reaction times, the pHiep was found to be above that of pure hematite, approaching that of yttrium basic carbonate or oxide. In particular, among the oxide-coated particles, it is sample OB9 the one that most closely approaches its pHiep to that of Y2O3, in good agreement with the surface chemical analysis performed with XPS. Copyright 1997 Academic Press. Copyright 1997Academic Press

Journal Article↗
PubMed2006

Study of yttrium containing bioactive glasses behaviour in simulated body fluid.

The influence of yttrium oxide on the bioactivity of glasses in the system SiO(2)-Na(2)O-P(2)O(5)-CaO-B(2)O(3)-K(2)O-MgO was studied in a simulated body fluid (SBF). Two series of glasses with different bioactivity were investigated. The reaction layers formed on the surface of the exposed glasses were evaluated by means of back scattered electron imaging of scanning electron microscopy equipped with energy dispersive X-ray analysis (BEI-SEM/EDXA). The concentration of Y, Ca and P released from the glasses into SBF, during 21 days was determined using inductively coupled plasma-emission spectroscopy ICP-AES and inductively coupled plasma-mass spectroscopy ICP-MS. Introducing yttrium in the selected bioactive glass tended to diminish the bioactivity of the glasses. The thickness of the calcium phosphate layer decreased with increasing yttrium oxide content. The same effect was also observed when yttrium oxide partially replaced only calcium, magnesium and phosphorous oxide in the precursor glass. The data show that we can produce bioactive glasses with yttrium oxide as a component. By suitable tailoring of the rest of the glasses the yttrium effect on the glass behavior in SBF should be possible to control and thus produce yttrium containing glasses with desired bioactivity.

Biocompatible Materials↗
PubMed1993

Yttrium synovectomy: a meta-analysis of the literature.

BACKGROUND: Yttrium synovectomy for chronic synovitis of the knee enjoys widespread usage in Australia with approximately 400 patients receiving yttrium-90 in 1991. Despite abundant anecdotal evidence of its efficacy there is a paucity of controlled trials and those that have been done have produced conflicting results and have been of insufficient sample size. AIMS: To critically and quantitatively evaluate the published English literature on comparative trials of yttrium-90 therapy for chronic synovitis of the knee. METHODS: The technique of meta-analysis was utilised. The literature search was carried out using the MeSH terms of synovectomy and knee; and yttrium. This was augmented by referring to reviews, current textbooks and back-references. Outcome measures varied between trials but could be grouped as treatment success. The Peto modification of Mantel and Haenszl was used for statistical pooling of data yielding a pooled odds ratio (OR). RESULTS: The literature search revealed ten controlled trials of which two were excluded from further analysis. Yttrium was superior to placebo (OR 2.42, 95% CI 1.02-5.73) but this result should be interpreted with caution due to possible publication bias. Yttrium was not superior to triamcinolone (OR 1.89, 95% CI 0.81-10.55) or other active modalities (OR 1.04, 95% CI 0.72-1.52). Further research comparing yttrium with other modalities is necessary to properly determine its place in rheumatological practice.

Anti-Inflammatory Agents↗
PubMed2006

Use of dipicolinate-based complexes for producing ion-imprinted polystyrene resins for the extraction of yttrium-90 and heavy lanthanide cations.

Highly selective separation of yttrium (and lanthanides) is of interest for the design of radiopharmaceuticals, and an efficient method based on the ion-imprinting concept is proposed here. The synthesis and structural, thermodynamic and photophysical characterization of complexes of trivalent yttrium and lanthanides with two new vinyl derivatives of dipicolinic acid, HL1 and L2, are described. The feasibility of using ion-imprinted resins for yttrium and lanthanide separation is demonstrated. The resins were obtained by copolymerization with styrene and divinylbenzene and subsequent acid treatment to remove the metal ion. High-resolution Eu luminescence experiments revealed that the geometry of the complexation sites is well preserved in the imprinted polymers. The ion-imprinted polymer based on HL1 proved to be particularly well adapted for yttrium extraction, having a sizeable capacity (8.9+/-0.2 mg g(-1) resin) and a fast rate of extraction (t(1/2)=1.7 min). In addition, lighter and heavier lanthanide ions are separated. Finally, the resin displays high selectivity for yttrium and lanthanide cations against alkali and alkaline earth metals. For instance, in a typical experiment, 10 mg of yttrium was extracted from 5 g of milk ash sample by 2 g of the resin. The good separation properties displayed by the resin based on HL1 open interesting perspectives for the production of highly pure (90)Y and radiolanthanides for medical applications, and for trace analysis of these radiochemicals in food and in the environment.

Cations↗
PubMed2003

Structural dependence of thermodynamics of alkene binding to yttrium alkyl complexes and of kinetics of alkyl migration to coordinated alkenes.

Agostic interactions in yttrium alkyls are structure dependent. Primary alkyl yttrium complexes have beta-CH(2) agostic interactions at low temperature, but a shift toward alpha-agostic interactions occurs on warming. For the more crowded beta-disubstituted yttrium alkyls, an alpha-CH(2) agostic interaction is seen. The thermodynamics of alkene binding to the primary alkyl yttrium complex Cp(2)YCH(2)CH(2)CH(CH(3))(2) (2) depend strongly on the structure of the alkene. A single allylic substituent on the alkene has a small effect on alkene binding, but a second allylic substituent has a large destabilizing effect. Propene binding to yttrium alkyls is largely independent of the nature of the alkyl ligand. Equilibrium constants for propene binding to n-, gamma-substituted, beta-substituted, and secondary alkyl yttrium complexes are similar. The rate of migration of an alkyl group to a coordinated alkene depends strongly on the structure of the alkyl group: n-alkyl approximately gamma-substituted >> beta-substituted >> alpha-substituted. The approximately 200-fold slower insertion of propene into Cp(2)YCH(2)CH(CH(3))(2) (6) than that into Cp(2)YCH(2)CH(2)CH(CH(3))(2) (2) is therefore due to kinetically slow migration of the beta-disubstituted alkyl group of 6 and not to differences in the equilibrium binding of propene. Processes related to chain transfer and site epimerization at the metal center are also reported.

Journal Article↗
PubMed2004

Yttrium-90 microspheres for the treatment of hepatocellular carcinoma.

Unresectable hepatocellular carcinoma is extremely difficult to treat. TheraSphere consists of yttrium-90 (a pure beta emitter) microspheres, which are injected into the hepatic arteries. This article reviews the safety and survival of patients with hepatocellular carcinoma who were treated with yttrium-90 microspheres. Eighty patients were selected from a database of 108 yttrium-90 microsphere-treated patients and were staged by using Child-Pugh, Okuda, and Cancer of the Liver Italian Program scoring systems. Patients were treated with local, regional, and whole-liver approaches. Survival from first treatment was analyzed with Kaplan-Meier and Cox regression methods. Adverse events and complications of treatment were coded by using the Southwest Oncology Group toxicity scoring system. Patients received liver doses ranging from 47 to 270 Gy. Thirty-two patients (40%) received more than 1 treatment. Survival correlated with pretreatment Cancer of the Liver Italian Program scores ( P = .002), as well as with the individual Cancer of the Liver Italian Program components, Child-Pugh class, alpha-fetoprotein levels, and percentage of tumor replacement. Patients classified as Okuda stage I (n = 54) and II (n = 26) had median survival durations and 1-year survival rates of 628 days and 63%, and 384 days and 51%, respectively ( P = .02). One patient died of liver failure judged as possibly related to treatment. Thus, in selected patients with hepatocellular carcinoma, yttrium-90 microsphere treatment is safe and well tolerated. On the basis of these results, a randomized controlled trial is warranted comparing yttrium-90 microsphere treatment with transarterial chemoembolization by using the Cancer of the Liver Italian Program system for prospective stratified randomization.

Aged↗